ISIS-APOCIII delivers strong trial results

|By:, SA News Editor

Final analysis of Isis Pharmaceuticals' (ISIS) antisense drug ISIS-APOCIII shows statistically significant reductions in triglycerides (64%) and apoC-III (71%) and apoC-III-associated VLDL in patients on stable doses of fibrates.

Average increase of HDL-C is 52%.

The 13-week Phase 2 study assessed the safety and activity of ISIS-APOCIII in 200 mg and 300 mg doses .

Phase III to commence this year.

Consensus total revenue estimates for Q1 and Q2 are $36.3M and $43.7M, respectively.

Consensus total revenue estimates for 2014 and 2015 are $156M and $164M, respectively.

406 mutual funds have positions, up from 235 a year earlier.